Risk analysis of cardiovascular toxicity in patients with lymphoma treated with CD19 CAR T cells
Abstract Background Anti-CD19 chimeric antigen receptor (CAR) T cell therapy is a common, yet highly efficient, cellular immunotherapy for lymphoma. However, many recent studies have reported on its cardiovascular (CV) toxicity. This study analyzes the cardiotoxicity of CD19 CAR T cell therapy in th...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BMC
2025-01-01
|
| Seri Bilgileri: | Journal of Translational Medicine |
| Konular: | |
| Online Erişim: | https://doi.org/10.1186/s12967-024-06035-4 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|
